NAD

The speaker explicitly states he does not use mitochondrial-targeted peptides including NAD, Mots-c, and SS-31, categorizing them as non-essential for his goals. He implies these compounds, while potentially legitimate, are not worth the cost for the average user pursuing body composition and general wellness. No mechanistic or clinical evidence is cited to support or refute their utility.

The speaker argues that consumers are wasting money by purchasing numerous peptides such as NAD, Mots-c, and SS-31, when a simple two-compound protocol can deliver equivalent or superior results. He claims this simplification can save 'thousands of dollars per month.' This is a cost-efficacy opinion with no comparative clinical or pharmacoeconomic data cited.

The speaker explicitly states he does not use NAD, Mots-c ('Matzi'), or SS-31, categorizing them as mitochondrial peptides that are not necessary for his goals. He implies these compounds represent unnecessary spending for most users. This is a dismissal based on personal opinion and self-reported experience, not a controlled comparison.